Table 1.

Prior treatments within “resistant disease” cohort

TissueDatePrior secondary therapiesARAR-V7Housekeeping
1BladderSeptember 30, 2013Abiraterone3+2+3+
2LiverApril 27, 2012Abiraterone3+3+3+
3Trans-urethral resection of prostateNovember 20, 2012Docetaxel, abiraterone, cabazitaxel, enzalutamide2+1+3+
4BladderNovember 27, 2014Abiraterone, enzalutamide3+3+3+
5LiverOctober 31, 2014Abiraterone3+2+2+
6Vertebral body decompressionJanuary 10, 2014Docetaxel, abiraterone, cabazitaxel, enzalutamide3+2+3+
7Vertebral body decompressionApril 30, 2010Bicalutamide3+2+3+
8BladderSeptember 29, 2010Abiraterone, docetaxel3+1+1+
9Vertebral body decompressionJanuary 25, 2014Bicalutamide3+1+3+
10BladderNovember 27, 2013Abiraterone3+3+3+
11FemurMarch 11, 2011Bicalutamide, docetaxel, cabazitaxel1+1+2+
12Soft tissue (autopsy)September 14, 2013Abiraterone1+3+3+
  • NOTE: “AR” and “AR-V7” denote androgen receptor transcript scoring by RNA ISH for full-length and AR-V7 splice variant, respectively. “Housekeeping” denotes housekeeping gene transcript scoring. All samples were positive for housekeeping gene staining at 1+ to 3+. The only sample that scored higher for AR-V7 than for AR was the autopsy sample.